antiplatelet agent

Imagine platelets as tiny sticky patches that rush to plug a cut. That is exactly what you want when you scrape your knee, but inside a diseased artery the same stickiness can pile up on a damaged plaque and choke off blood flow. Antiplatelet agents are a drug class that turns down this stickiness, making platelets less likely to clump where they would do harm.

Platelets normally activate and glue together through several chemical signals. Different antiplatelet drugs block different signals: aspirin blocks the enzyme that makes thromboxane, while drugs like clopidogrel block a receptor called P2Y12. Because each works on a separate step, two of them are sometimes combined after a stent or heart attack — a strategy called dual antiplatelet therapy.

These drugs are central to preventing clots in arteries, especially in coronary artery disease, after stents, and after some strokes. The trade-off is bleeding: anything that makes clotting harder can turn a minor injury or a stomach ulcer into a real problem, so the choice and duration are weighed against each person's bleeding risk.

Antiplatelet drugs are not the same as anticoagulants. Both reduce clotting, but antiplatelets mainly target the fast platelet plug typical of high-pressure arteries, while anticoagulants slow the slower clotting-protein cascade that dominates in veins and the fibrillating atrium.